- Trials with a EudraCT protocol (132)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (10)
132 result(s) found for: tuberculosis.
Displaying page 1 of 7.
EudraCT Number: 2019-002063-95 | Sponsor Protocol Number: ASST-ITL-FARMA-INFE-2019 | Start Date*: 2020-05-29 | ||||||||||||||||
Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA | ||||||||||||||||||
Full Title: A Phase 3, Open, Randomized controlled trial on Completion Rate of daily Rifapentine/Isoniazid for One Month Compared with Daily Rifampicin/Isoniazid for Three Months for the Treatment of Latent Tu... | ||||||||||||||||||
Medical condition: latent tuberculosis infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000653-23 | Sponsor Protocol Number: TMC207-TiDP13-C210 | Start Date*: 2012-06-13 | |||||||||||
Sponsor Name:Janssen Infectious Diseases BVBA | |||||||||||||
Full Title: A Phase III placebo-controlled, double-blind, randomized trial to evaluate the efficacy and safety of TMC207 in subjects with sputum smear-positive pulmonary infection with multi-drug resistant Myc... | |||||||||||||
Medical condition: Multi-drug resistant tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Prematurely Ended) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021125-12 | Sponsor Protocol Number: TMC207TBC3001 | Start Date*: 2011-09-16 | |||||||||||
Sponsor Name:Janssen Infectious Diseases BVBA | |||||||||||||
Full Title: Early access of TMC207 in combination with other anti-tuberculosis (TB) drugs in subjects with extensively drug resistant (XDR) or pre-XDR pulmonary TB | |||||||||||||
Medical condition: Tuberculosis (TB) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005617-36 | Sponsor Protocol Number: TESEC-06 | Start Date*: 2012-05-30 | |||||||||||
Sponsor Name:Statens Serum Institut | |||||||||||||
Full Title: A phase III contact tracing trial comparing the diagnostic performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in combination with a double blind randomized split body safety assessment of C-Tb ve... | |||||||||||||
Medical condition: Tuberculosis diagnostic tool | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000224-41 | Sponsor Protocol Number: IDANAT2 | Start Date*: 2008-08-26 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: A double-blind, multicentre, parallel group, randomised, controlled trial to evaluate the possible benefit of isoniazid dose adjustment according to the genotype for NAT2 (arylamine N-acetyltransfe... | |||||||||||||
Medical condition: pulmonary tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022271-59 | Sponsor Protocol Number: 242-09-213 | Start Date*: 2011-07-19 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of Delamanid (OPC-67683) Administered Orally as 200 mg Total Daily Dos... | |||||||||||||
Medical condition: Pulmonary Multidrug-resistant Tuberculosis (MDR TB) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) EE (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000632-27 | Sponsor Protocol Number: PORT-01 | Start Date*: 2022-08-03 |
Sponsor Name:Radboud University Medical Center | ||
Full Title: Pragmatic trial on the safety and tolerability of an optimized dose of rifampicin in tuberculosis patients | ||
Medical condition: Tuberculosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) DK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022302-41 | Sponsor Protocol Number: FLISH-ILT | Start Date*: 2011-03-03 | ||||||||||||||||
Sponsor Name:Consorcio de Apoyo a la Investigación Biomédica en Red (CAIBER) | ||||||||||||||||||
Full Title: Ensayo clínico prospectivo, aleatorizado, comparativo de la eficacia y seguridad del levofloxacino versus isoniazida en el tratamiento de la infección latente tuberculosa del trasplante hepático | ||||||||||||||||||
Medical condition: Pacientes en lista de espera de trasplante hepático | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005664-88 | Sponsor Protocol Number: HB996 | Start Date*: 2006-12-08 |
Sponsor Name:University of Oxford | ||
Full Title: Prospective Study of Mycobacterium Tuberculosis Specific Cellular immune Responses in Iatrogenically Immunosuppressed Patients: those undergoing TNF-alpha blockade or Awaiting Renal Trasnplants: A ... | ||
Medical condition: Renal failure and iatrogenic immunosuppression associated with solid organ transplantation or TNF alpha blockade in rheumatoid arthritis ICD 10 codes included: N18 Z94.0 M05 M06 M07 M45 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-023189-27 | Sponsor Protocol Number: RG-10-179 | Start Date*: 2011-01-20 |
Sponsor Name:University of Birmingham | ||
Full Title: The pharmacogenetics of vitamin D response in tuberculosis | ||
Medical condition: Tuberculosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003446-45 | Sponsor Protocol Number: TBTCS31/A5349 | Start Date*: 2016-02-25 |
Sponsor Name:Unidad de investigación en Tuberculosis de Barcelona | ||
Full Title: Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial | ||
Medical condition: Pulmonary tuberculosis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002094-58 | Sponsor Protocol Number: UITB-TBTC-Estudio33 | Start Date*: 2012-10-26 |
Sponsor Name:Unidad de Investigación en Tuberculosis de Barcelona (UITB) | ||
Full Title: An evaluation of adherence to LTBI treatment with 12 doses of once weekly rifapentine and isoniazid given as self-administered versus directly-observed therapy: iAdhere | ||
Medical condition: Adherence study in subjects with Latent Tuberculosis Infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003753-13 | Sponsor Protocol Number: P160909 | Start Date*: 2019-03-19 |
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | ||
Full Title: Multicentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis | ||
Medical condition: Patients with refractory or relapsing Takayasu Arteritis desease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002111-22 | Sponsor Protocol Number: BCG/COVID-19/UR/04/2020 | Start Date*: 2020-06-26 |
Sponsor Name:University of Rzeszów | ||
Full Title: A multi-centre, randomised, double-blind, placebo-controlled phase III study assessing the impact of BCG vaccination on the incidence and course of SARS-CoV-2 infection among healthcare workers in ... | ||
Medical condition: not applicable | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005078-40 | Sponsor Protocol Number: TESEC-05 | Start Date*: 2016-06-03 |
Sponsor Name:Statens Serum Institut | ||
Full Title: A Phase III trial in subjects suspected to have tuberculosis, comparing the diagnostic performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in combination with a double blind randomised splitbody s... | ||
Medical condition: Children (28 days–4 years old) with suspected Mycobacterium tuberculosis infection Participants between 5–65 years old who attended the TB clinic due to suspicion of TB disease (HIV positive and HI... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2020-005205-42 | Sponsor Protocol Number: 20200417 | Start Date*: 2021-06-23 | |||||||||||
Sponsor Name:Amgen, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blinded Study Evaluating the Pharmacokinetics, Efficacy and Safety of Multiple Switches Between Ustekinumab and ABP 654 Compared With Continued Use of Ustekinumab ... | |||||||||||||
Medical condition: Moderate to severe plaque psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) LV (Completed) EE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003177-99 | Sponsor Protocol Number: A3921133 | Start Date*: 2014-07-10 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) SE (Completed) FI (Completed) NL (Completed) SK (Completed) GB (Completed) ES (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000358-13 | Sponsor Protocol Number: A3921187 | Start Date*: 2014-12-04 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 3b/4 RANDOMIZED DOUBLE BLIND STUDY OF 5 MG OF TOFACITINIB WITH AND WITHOUT METHOTREXATE IN COMPARISON TO ADALIMUMAB WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATO... | |||||||||||||
Medical condition: Moderately to severely active Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) EE (Completed) LT (Completed) LV (Completed) GB (Completed) ES (Completed) PL (Completed) BG (Completed) RO (Completed) DE (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000537-12 | Sponsor Protocol Number: 20120263 | Start Date*: 2013-09-25 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Phase 3, Multicenter, randomized, double-blind study evaluating the efficacy and safety of ABP 501 compared with Adalimumab in subjects with moderate to severe plaque psoriasis | |||||||||||||
Medical condition: Moderate to Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) PL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002012-13 | Sponsor Protocol Number: CNTO1275PSO4054 | Start Date*: 2017-10-04 | ||||||||||||||||
Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS | ||||||||||||||||||
Full Title: EXPLORATIVE STUDY ON THE BIOLOGICAL MECHANISMS INVOLVED IN THE PATHOGENESIS OF PSORIASIS | ||||||||||||||||||
Medical condition: Moderate to severe psoriasis. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
